Tampere University

Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy developmentHOLLISTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Safety Pharmacology Society (SPS) Annual Meeting being held from September 22-25, 2024, in San Diego. DSI™ Ponemah™ Data Management Platform Provides Integrated Preclinical Solution The Company’s Ponemah™ platform, known for its compliance with GLP standards, is a leading tool for managing and analyzing data from a wide range of preclinical studies. It now integrates with DSI’s SoHo™ implantable telemetry and high-capacity VivaMARS™ behavior monitoring systems. Ponemah is the top solution for collecting and processing large in-vivo data sets and is well positioned to connect in-vivo studies with new in-vitro methods, like our Mesh MEA™ organoid platform. Ponemah also enables future use of machine learning algorithms to efficiently analyze large data pools. SoHo™ Implantable Real-Time Telemetry for Small Animal Models Introduced earlier this year, the Company’s SoHo telemetry system is now in use by leading preclinical researchers to support their testing needs. The small footprint of the SoHo telemetry solution allows researchers to carry out studies using a wide range of animal models in high density and more natural shared housing environments. The SoHo system’s new power management features create opportunities for longer duration longitudinal studies, and the Ponemah platform integration provides a powerful tool for collecting, managing, analyzing and reporting study data. SoHo supports the customer’s business needs by reducing space needs, operating costs and test cycle times, and enabling increased testing throughput. For more information, visit the DSI website at https://www.datasci.com/products/implantable-telemetry/soho-telemetry-system. VivaMARS™ Activity Monitoring System The VivaMARS system provides a powerful and efficient platform for real-time, high-throughput behavioral testing in neuropharmacology safety and toxicology studies. Coupled with the Ponemah platform, the VivaMARS system provides an integrated, GLP-compliant solution ideally suited to meet the testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes. VivaMARS’s high level of automation supports the customer’s business needs by reducing operating expenses and test cycle time. At SPS, the Company will be presenting a poster authored in cooperation with a leading CRO customer providing initial results with the VivaMARS system. The VivaMARS system represents a fundamental advance in highly automated behavioral testing and is currently available for shipment. For more information on the VivaMARS system, visit the DSI website at https://www.datasci.com/products/behavior/vivamars-mobile-activity-rack-system. MCS™ Mesh MEA™ Organoid Platform The Company will also be highlighting its considerable progress toward adoption of its organoid-centric mesh Microelectrode Array (MEA) platform. Designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology, the new Mesh MEA™ platform allows researchers to capture precise electrophysiology measurements from inside the living organoid in real time. In addition, the Mesh MEA platform is expected to provide an efficient in-vitro screening option designed to reduce large population small model testing. The Mesh MEA™ platform is currently being evaluated at select test sites for neurological and cardiac research in addition to safety pharmacology and toxicology applications. The Company has also begun limited quantity shipments to early adopters, with full production expected in the first half of 2025. For more information on the Company’s mesh MEA products and organoid research, visit our website at https://www.harvardbioscience.com/applications/organoid-research. Solutions for New Therapy Development Jim Green, Harvard Bioscience Chairman and CEO, said, “This year’s Safety Pharmacology Society Conference demonstrates our continued commercial success in advancing our industry leading wireless telemetry line with the first production sales of our new SoHo implants. In addition, we’re excited to collaborate with a leading customer to present compelling data with the VivaMARS neuro-behavior system. We expect additional system installations in the upcoming months as further proof of VivaMARS’ value proposition. Finally, we’re extremely excited to see continuing expansion of our breakthrough Mesh MEA Organoid Systems with multiple beta sites now in operation plus additional installations going to leading biotech, pharma and CRO companies in addition to top academic institutions such as University of Michigan and Tampere University. Booth at the Safety Pharmacology Society Annual Meeting The Company will be exhibiting a range of solutions at the Safety Pharmacology Society Annual Meeting booth 501, at the Town and Country Resort, 500 Hotel Circle N, San Diego, CA 92108. Representatives will be available September 23-24 from 9:00 am – 5:00 pm. About Harvard Bioscience Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at https://www.harvardbioscience.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Harvard Bioscience, Inc. (the “Company”) market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available. Inquiries CustomersInfo@harvardbioscience.com Investors and MediaHarvard Bioscience, Inc.Investor Relationsinvestors@harvardbioscience.com(508) 893-3120

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the potential importance of VCIEL for CeD research and clinical trials BOCA RATON, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced the publication of “A Composite Morphometric Duodenal Biopsy Mucosal Scale for Celiac Disease Encompassing Both Morphology and Inflammation” in Clinical Gastroenterology and Hepatology, a pre-eminent journal of the American Gastroenterological Association (AGA) that publishes innovative diagnostic and therapeutic advances in clinical gastroenterology. As the number of promising therapies for celiac disease (CeD) grows, so does the need to improve the measurement of clinically relevant histological endpoints. The new approach presented in a peer-reviewed publication, led by Jack Syage, Ph.D., President and Chief Scientific Officer of Entero Therapeutics, recognized the need to advance beyond qualitative measures of histologic small intestinal health and to develop a more accurate and sensitive scale based on the independent quantitative measures of architectural changes (villus height to crypt depth ratio, Vh:Cd) and inflammation (intraepithelial lymphocyte count, IEL) already in use. The team created a composite score (VCIEL) for these two measures that helps overcome the individual variances to improve the overall accuracy of histological evaluation. The publication demonstrated the significant benefits of the VCIEL scale based on the results of four previous clinical trials. The significance of this achievement was highlighted in a special editorial feature by the journal, demonstrating the importance of this novel metric to CeD researchers. “VCIEL can provide a higher predictive value to evaluate the efficacy of adjunct therapies in development,” stated Markku Mӓki, M.D., Ph.D., Faculty of Medicine and Health Technology at Tampere University and co-author of the publication. “We believe that using VCIEL will result in a more accurate histological assessment for CeD patients and greater sensitivity in measuring therapeutic benefit. With this approach, we anticipate an enhanced ability to address unmet need in the Celiac community.” “We believe the development of VCIEL represents a significant step forward in the management of Celiac Disease and offers new possibilities for improving patient care and treatment outcomes,” stated Dr. Syage. “Moving forward, we anticipate further validation of VCIEL through future clinical trials, including our Phase 3 latiglutenase study, with the aim of establishing a new gold standard for measuring clinically meaningful responsiveness to treatment.” About Latiglutenase Latiglutenase, an oral biotherapeutic comprising two gluten-specific recombinant enzymes, is being developed to treat celiac disease in conjunction with a gluten-free diet. It has demonstrated efficacy in alleviating GI symptoms of celiac disease and preventing or improving intestinal damage in Phase 2 trials. The Phase 3 clinical program for latiglutenase is being discussed with the GI Division of the U.S. Food and Drug Administration (FDA), and the initiation of the Phase 3 trials is expected in early 2025. About Celiac Disease Celiac disease (CeD) is a chronic, autoimmune disease in which eating gluten (a protein found in wheat, rye, and barley) causes damage to the lining of the small intestine, leading to malabsorption. CeD can present with highly variable gastrointestinal and extra-intestinal clinical manifestations, including anemia, chronic migraine, peripheral neuropathy, cognitive impairment, vitamin B-12 deficiency, unexplained infertility, and others that impact activities of daily living and increased healthcare costs. Currently, the only treatment for CeD is life-long adherence to a strict gluten-free diet. About one-third of patients on a gluten-free diet persist with symptoms or malabsorption signs. The seroprevalence of Celiac disease in adults is approximately 1.4% of the worldwide population. About Entero Therapeutics, Inc. Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around its proprietary technologies, including: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for Celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Entero Therapeutics is headquartered in Boca Raton, Florida. For more information visit . Forward-Looking Statements This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether any financing or licensing transaction may be completed, completed with different terms, in an untimely manner, or not at all; whether the Company will be able to realize the expected benefits of its acquisition of ImmunogenX; the Company’s ability to integrate the assets and contemplated commercial operations acquired from ImmunogenX into the Company’s business; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to maintain compliance with Nasdaq’s continued listing criteria and the effect of a delisting from Nasdaq on the market for the Company’s securities; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financial prospects; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. For more information: Entero Therapeutics, Inc. 777 Yamato Road, Suite 502 Boca Raton, FL 33431 Phone: (561) 589-7020 info@enterothera.com Media contact: Russo Partners David Schull or Liz Phillips (347) 956-7697 david.schull@russopartnersllc.com elizabeth.phillips@russopartnersllc.com

Researchers have developed a tiny robot replicating the aerial dance of falling maple seeds. In the future, this robot could be used for real-time environmental monitoring or delivery of small samples even in inaccessible terrain such as deserts, mountains or cliffs, or the open sea. This technology could be a game changer for fields such as search-and-rescue, endangered species studies, or infrastructure monitoring. Researchers from Tampere University, Finland, and the University of Pittsburgh, USA, have developed a tiny robot replicating the aerial dance of falling maple seeds. In the future, this robot could be used for real-time environmental monitoring or delivery of small samples even in inaccessible terrain such as deserts, mountains or cliffs, or the open sea. This technology could be a game changer for fields such as search-and-rescue, endangered species studies, or infrastructure monitoring. At Tampere University, Professor Hao Zeng and Doctoral Researcher Jianfeng Yang workat the interface between physics, soft mechanics, and material engineering in their Light Robots research group. They have drawn inspiration from nature todesign polymeric gliding structures that can be controlled using light. Now, Zeng and Yang, with Professor M. Ravi Shankar,from the University of Pittsburgh Swanson School of Engineering, utilized a light-activated smart material to control the gliding mode of an artificial maple seed. In nature, maple disperse to new growth sites with the help of flying wings in their samara, or dry fruit. The wings help the seed to rotate as it falls, allowing it to glide in a gentle breeze. The configuration of these wings defines their glide path. According to the researchers, the artificial maple seed can be actively controlled using light, where its dispersal in the wind can be actively tuned to achieve a range of gliding trajectories. In the future, it can also be equipped with various microsensors for environmental monitoring or be used to deliver, for example, small samples of soil. Hi-tech robot beats natural seed in adaptability The researchers were inspired by the variety of gliding seeds of Finnish trees, each exhibiting a unique and mesmerizing flight pattern. Their fundamental question was whether the structure of these seeds could be recreated using artificial materials to achieve a similar airborne elegance controlled by light. "The tiny light-controlled robots are designed to be released into the atmosphere, utilizing passive flight to disperse widely through interactions with surrounding airflows. Equipped with GPS and various sensors, they can provide real-time monitoring of local environmental indicators like pH levels and heavy metal concentrations" explains Yang. Inspired by natural maple samara, the team created azobenzene-based light-deformable liquid crystal elastomer that achieves reversible photochemical deformation to finely tune the aerodynamic properties. "The artificial maple seeds outperform their natural counterparts in adjustable terminal velocity, rotation rate, and hovering positions, enhancing wind-assisted long-distance travel through self-rotation," says Zeng. In the beginning of 2023 Zeng and Yang released their first, dandelion seed like mini robot within the projectFlying Aero-robots based on Light Responsive Materials Assembly -- FAIRY. The project, funded by the Research Council of Finland, started in September 2021, and will continue until August 2026. "Whether it is seeds or bacteria or insects, nature provides them with clever templates to move, feed and reproduce. Often this comes via a simple, but remarkably functional, mechanical design," Shankar explains. "Thanks to advances in materials that are photosensitive, we are able to dictate mechanical behavior at almost the molecular level. We now have the potential to create micro robots, drones, and probes that can not only reach inaccessible areas but also relay critical information to the user. This could be a game changer for fields such as search-and-rescue, endangered or invasive species studies, or infrastructure monitoring," he adds.